Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201.

Smartsheet Inc Cl A (SMAR)

$46.90 0.57 (1.20%)

19:00 EDT SMAR Stock Quote Delayed 30 Minutes

Volume:

Previous Close $46.90

Market Cap 545.63M

PE Ratio -54.53

EPS -0.86

Volume (Avg. Vol.) 2.23M

Day's Range 44.44 - 47.13

52-Week Range 30.91 - 60.45

Dividend & Yield N/A (N/A)

SMAR Stock Predictions, Articles, and Smartsheet Inc Cl A News

From InvestorPlace
From the Web

7 Strong Buy Stocks That Tick All the Boxes

By Harriet Lefton, Writer, TipRanks May 6, 2019

With the bull market continuing at a breakneck pace, you want to look for strong buy stocks with plenty of support in case of pullback.

Smartsheet News: Why SMAR Stock Is Rallying

By Karl Utermohlen, InvestorPlace Writer Mar 20, 2019

In the latest Smartsheet news, the company's stock is soaring more than 7% Wednesday as the cloud-based work platform's earnings impressed.

10 Cheap Stocks You Won’t Regret Buying

By Harriet Lefton, Writer, TipRanks Nov 21, 2018

Even in this choppy market, there are still good stocks to buy that won't break the bank. Here are some cheap stocks you won't regret.

7 Stocks to Buy According to Five-Star Analysts

By Harriet Lefton, Writer, TipRanks Oct 26, 2018

Volatility has hit hard again this October, but there are still stocks to buy. Here I used TipRanks to find 7 favorite 'Strong Buy' stocks from analysts with a proven track record of success.

Is Ovid Therapeutics Stock a Buy?

From The Motley Fool Jul 14, 2020

One analyst thinks the stock still has significant upside. Is that enough to justify its price?

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Ovid Therapeutics (OVID)

From Analyst Ratings Jul 13, 2020

Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Ovid Therapeutics (OVID – Research Report) today and set a price target of $21.00. The company’s shares closed last Monday at $7.79. According to TipRanks.com, Higgins has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.1%

Ovid closes gaboxadol commercialization deal in Europe (NASDAQ:OVID)

From Seeking Alpha Jul 13, 2020

Ovid Therapeutics (NASDAQ:OVID) inks an agreement with Italian drugmaker Angelini Pharma S.p.A. for the development, manufacture and commercialization of OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the EU, Switzerland, Turkey, UK and Russia.Under the terms of the deal, OVID will receive $20M upfront, up to $212.5M in milestones and double-digit royalties on net sales.OVID will retain the rights in the U.S.

REGN, NIO, GERN and SLCA among after-hours movers

From Seeking Alpha Jul 2, 2020

Gainers: APT +3.8%. IMMU +3.6%. QTT +3.5%. NIO +3.2%. SLCA +3%.Losers: TDC -3.3%. GERN -2.7%. OVID -2.6%. REGN -1.8%. MITT -1.7%.

Provention Bio and Ovid Therapeutics to join key indexes (NASDAQ:PRVB)

From Seeking Alpha Jun 29, 2020

Provention Bio (NASDAQ:PRVB) and Ovid Therapeutics (NASDAQ:OVID) has been added to the broad-market Russell 3000 and the small-cap Russell 2000 Indexes.

Provention Bio and Ovid Therapeutics joins Russell 2000 and 3000 Indexes (NASDAQ:PRVB)

From Seeking Alpha Jun 29, 2020

Provention Bio (NASDAQ:PRVB) and Ovid Therapeutics (NASDAQ:OVID) has been added to the broad-market Russell 3000 and the small-cap Russell 2000 Indexes.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy